Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Dec 15, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Biocartis said today that its tissue-based Idylla NRAS-BRAF mutation test has been CE marked and can now be sold throughout the European Economic Area.

According to the company, the combination of the new NRAS-BRAF mutation test with its existing KRAS assay means that it can offer customers a complete solution for clinical testing of metastatic colorectal cancers, as recommended by the most recent professional guidelines.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

What's Popular?

In Molecular Diagnostics

  1. NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

  2. Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

  3. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

    Premium

  4. Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches

    Premium

  5. Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.